Resolution of the Expert Council on the issues of diagnosis and treatment of myeloproliferative neoplasms, existing standards and the possibility of their implementation in real clinical practice in Russia

1. Subortseva I.N., Melikyan A.L. Chabaeva Yu.A. et al. Preliminary results of the Register of patients with myelofibrosis and polycythemia vera with constitutional symptoms in routine clinical practice in the Russian Federation. Gematologiya i transfuziologiya = Hematology and Transfusiology 2022;67(2):305. (In Russ.).

2. Melikyan A., Subortseva I., Baryshniikova D. et al. Epidemiological, clinical, molecular and genetic characteristics of primary myelofibrosis in the Russian Federation. HemaSphere 2019;3(S1):994–5.

3. Abdulkadyrov K.M., Shuvaev V.A., Martynkevich I.S. Myeloproliferative neoplasms. Saint Petersburg: Litterra; Moscow: Litterra, 2016. 298 p. (In Russ.).

4. Orphanet. Prevalence of rare diseases: Bibliographic data. In: Orphanet Report Series, Rare Diseases Collection. Ed.: C. Gonthier. 2011. P. 13.

5. Arber D.A., Orazi A., Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391–405. DOI: 10.1182/blood­2016­03­643544

6. Melikyan A.L., Kovrigina A.M., Subortseva I.N. et al. National сlinical recommendations for diagnosis and therapy of Ph­negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2018). Gematologiya i transfuziologiya = Hematology and Transfusiology 2018;63(3):275–315. (In Russ.).

7. Melikyan A.L., Kovrigina A.M., Subortseva I.N. et al. National clinical guidelines on diagnosis and treatment of Ph­negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, and primary myelofibrosis) (edition 2020). Klinicheskaya onkogematologiya = Clinical Oncohematology 2021;14(2):262–98. (In Russ.). DOI: 10.21320/2500­2139­2021­14­2­262­298

8. Harris N.L., Jaffe E.S., Diebold J. et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. J Clin Oncol 1999;17(12):3835–49. DOI: 10.1200/ JCO.1999.17.12.3835

9. Cervantes F., Dupriez B., Pereira A. et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113(13):2895–901. DOI: 10.1182/ blood­2008­07­170449

10. Melikyan A.L., Subortseva I.N., Shuvaev V.A. et al. Current view on diagnosis and treatment of classical Ph­negative myeloproliferative neoplasms. Klinicheskaya onkogematologiya = Clinical Oncohematology 2021;14(1)129–37. (In Russ.). DOI: 10.21320/2500­2139­2021­14­1­129­137

11. Ionova T.I., Andreevskaya E.A., Babich E.N. et al. Current qualityof­life aspects in patients with classical Ph­negative myeloproliferative neoplasms in the Russian Federation: results and discussion of the national observational program MPN­QoL­2020. Klinicheskaya onkogematologiya = Clinical Oncohematology 2022;15(2):176–97. (In Russ.). DOI: 10.21320/2500­2139­2022­15­2­176­197

12. Melikyan A.L., Subortseva I.N. Current issues of targeted therapy of polycythemia vera. Klinicheskaya onkogematologiya = Clinical Oncohematology 2021;14(3):355–60. (In Russ.). DOI: 10.21320/2500­2139­2021­14­3­355­360

13. Lomaia E.G., Siordiya N.T., Senderova O.M. et al. Early response and long­term outcomes of ruxolitinib therapy in myelofibrosis: multicenter retrospective study in 10 centers of the Russian Federation. Klinicheskaya onkogematologiya = Clinical Oncohematology 2020;13(3):335–45. (In Russ.). DOI: 10.21320/2500­2139­2020­13­3­335­345

14. Vinogradova O.Yu., Shuvaev V.A., Martynkevich I.S. et al. Targeted therapy of myelofibrosis. Klinicheskaya onkogematologiya = Clinical Oncohematology 2017;10(4):471–8. (In Russ.). DOI: 10.21320/2500­2139­2017­10­4­471­478

15. Vannucchi A.M., Guglielmelli P., Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009;59(3):171–91. DOI: 10.3322/caac.20009